{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-073284","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.431457+00:00","generated_at":"2026-06-24T23:50:22.322824+00:00","sec_items":["3.02","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rockwell Medical CEO Russell Ellison steps down; Mark Strobeck appointed CEO; DaVita gets $7.5M preferred stock","bullets":["CEO Russell Ellison steps down effective June 30, 2022; severance includes $500K base salary and $350K target bonus over 12 months plus option vesting extension.","Mark Strobeck appointed President and CEO effective July 1, 2022; base salary $550K, target bonus 60%, initial time-based option grant of 400,000 shares.","Issued additional 7,500 shares of Series X Convertible Preferred Stock to DaVita on June 16, 2022 for gross proceeds of $7.5 million (second closing under SPA).","Dr. Strobeck also appointed to the Board as a Class III director with term through 2024 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-073284","json":"https://secwatch.observer/filing/0001104659-22-073284.json","markdown":"https://secwatch.observer/filing/0001104659-22-073284.md","text":"https://secwatch.observer/filing/0001104659-22-073284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/tm2219051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:50:22.322824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82dafd5881","claim":"Mark Strobeck was appointed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..","evidence_excerpt":"the Board appointed Mark Strobeck, Ph.D. as the Company’s President and Chief Executive Officer and as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective July 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ad4ff6b98a","claim":"Russell H. Ellison departed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..","evidence_excerpt":"Russell H. Ellison, M.D., M.Sc., will be stepping down from his role as the President and Chief Executive Officer of the Company, effective as of June 30, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}